MedTrace Logo

Rifaximin Use in Severe Alcoholic Hepatitis

NCT02485106 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2015-06-30

No results posted yet for this study

Summary

This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.

Conditions

  • Severe Alcoholic Hepatitis

Interventions

DRUG

Rifaximin

400mg three times per day for 28 days

DRUG

Corticosteroid or pentoxifylline

Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days

Sponsors & Collaborators

  • Saint Vincent's Hospital, Korea

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02485106 on ClinicalTrials.gov